AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024 Life Science Investing
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares Life Science Investing
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy portfolio Life Science Investing
Novartis presents latest Phase III Fabhalta® data in C3 glomerulopathy showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo Life Science Investing
Ocumetics Announces Completion of First Tranche of Debenture Private Placement for Net Proceeds of CA$2.82 Million Geography
